An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab.
To evaluate the impact of abbreviated therapeutic plasma exchange (TPE) on platelet count recovery in patients with immune thrombotic thrombocytopenic purpura (iTTP) receiving caplacizumab.
Conducted a randomized trial comparing traditional TPE duration to an abbreviated course.
Evaluated platelet counts post-TPE cessation in patients treated with caplacizumab.
No significant difference in platelet count recovery was observed between abbreviated and traditional TPE groups.
Patients experienced durable platelet recovery regardless of TPE duration.
Abstract
/L and observed no detriment with early TPE cessation. Additional high-quality studies re-evaluating daily TPE cessation endpoints are needed for patients with iTTP receiving caplacizumab.